Abstracts, Publications, and Presentations


2013 ASH Abstracts

2013 ASCO Abstracts

2012 ASH Abstracts

2011 ASH Abstracts

2010 ASH Abstracts

Selected Publications







For a more extensive list of publications visit PubMed.


In addition, physicians and researchers at the UAMS Myeloma Institute for Research and Therapy routinely present at national and international conferences and scientific meetings. To learn more about our findings, please use the links listed below.

Five Gene Probes Carry Most Of The Discriminatory Power Of The 70-Gene Risk Model In Multiple Myeloma

2013 ASH Poster Presentations

Cure of Myeloma

 PACMED Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM)

Autotransplants for Multiple Myeloma (MM)

Abnormally High Levels of E- and N-Cadherin Expression Consequences of Intermittent PTH Treatment on Myeloma Growth, Bone Disease and Molecular Profiling of Whole Myelomatous Bone.

Myeloma Cell Interaction with Osteoclasts and Mesenchymal Stem Cells Reveals Genes Associated with Post Relapse Survival.

Gene Expression Profiling (GEP)

Human Placenta-Derived Adherent Cells Stem Cells Primarily Traffic to Mesenteric Lymph Nodes

DKK1 is an Immediate Early Gene in Multiple Myeloma Cells Modulated by Cell Density and IL-6

Improved Outcome with Total Therapy 3 (TT3)

Modeling for the Cure: Total Therapy Trials for Newly Diagnosed Multiple Myeloma: Let the Math Speak!

Confirmed in Successor Protocol Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth in Vivo

Clinical Research in Multiple Myeloma: Linking Outcomes to Genomics of Both Tumor & Normal Host Cells 

The Myth of Incurability   90% CR Sustained 4 Years After Onset of CR in Gene Array-Defined Low-Risk Myeloma Treated With Total Therapy 3: Basis for Risk-Adapted TT4 AND TT5 

Hematologic Malignancies in the Aging Population: Biology, Molecular Prognostic Markers and Novel Treatment Strategies

Total Therapy for Multiple Myeloma: Evolution from Palliation to Cure during 20 Years of Clinical Research

Listen to Presentations:

Frits van Rhee, MD, PhD Total Therapy program on CurePanel

John Shaughnessy, PhD Towards a Molecular-Based Risk Stratification of Multiple Myeloma

Joshua Epstein, DSc The Scid-hu model for Multiple Myeloma

Bart Barlogie, MD, PhD, Debate II – Should autologous transplant be part of the primary treatment in mm? YES